{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:55:31Z","timestamp":1794099331216,"version":"4.8.0"},"reference-count":37,"publisher":null,"issue":"7","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>The review focuses on upper gastrointestinal (GI) bleeding in patients with ischemic heart disease (IHD) receiving an antithrombotic therapy. Approaches to risk stratification for GI bleeding and correction of modifiable factors that determine the probability of such events are addressed in detail. Recommendations are provided for administration of stomach-protecting drugs. The interrelation of risk factors for thromboses and bleedings is stressed, and possible indications for a multicomponent antithrombotic therapy in patients with stable IHD are discussed.<\/jats:p>","DOI":"10.18087\/cardio.2020.7.n1159","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T09:30:18Z","timestamp":1604655018000},"page":"115-124","source":"Crossref","is-referenced-by-count":1,"title":["The balance of benefit and risk in prescribing antithrombotic therapy for patients with coronary artery disease. How to deal with the gastrointestinal bleeding problem?"],"prefix":"10.68900","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9141-103X","authenticated-orcid":true,"given":"A. L.","family":"Komarov","sequence":"first","affiliation":[{"name":"National Medical Research Center of Cardiology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-1892","authenticated-orcid":true,"given":"O. O.","family":"Shakhmatova","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Cardiology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-9177","authenticated-orcid":true,"given":"V. V.","family":"Korobkova","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Cardiology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations from the International Consensus Group. Annals of Internal Medicine. 2019;171(11):805\u201322. DOI: 10.7326\/M19-1795","DOI":"10.7326\/M19-1795"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gralnek I, Dumonceau J-M, Kuipers E, Lanas A, Sanders D, Kurien M et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(10):a1\u201346. DOI: 10.1055\/s-0034-1393172","DOI":"10.1055\/s-0034-1393172"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373(9678):1849\u201360. DOI: 10.1016\/S0140-6736(09)60503-1","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sehested TSG, Carlson N, Hansen PW, Gerds TA, Charlot MG, TorpPedersen C et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. European Heart Journal. 2019;40(24):1963\u201370. DOI: 10.1093\/eurheartj\/ehz104","DOI":"10.1093\/eurheartj\/ehz104"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Khan MY, Siddiqui WJ, Alvarez C, Aggarwal S, Hasni SF, Ahmad A et al. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology. 2018;30(8):847\u201353. DOI: 10.1097\/MEG.0000000000001125","DOI":"10.1097\/MEG.0000000000001125"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. MetaAnalysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients with Atrial Fibrillation. The American Journal of Cardiology. 2012;110(3):453\u2013 60. DOI: 10.1016\/j.amjcard.2012.03.049","DOI":"10.1016\/j.amjcard.2012.03.049"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Girardin M, Bertolini D, Ditisheim S, Frossard J-L, Giostra E, Goossens N et al. Use of glasgow-blatchford bleeding score reduces hospital stay duration and costs for patients with low-risk upper GI bleeding. Endoscopy International Open. 2014;02(02):E74\u20139. DOI: 10.1055\/s-0034-1365542","DOI":"10.1055\/s-0034-1365542"},{"key":"ref8","unstructured":"Panchenko E.P., Komarov A.L., Shakhmatova O.O., Yarovaya E.B., Shuleshova A.G. Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients with Chronic Coronary Syndromes. \u2116 NCT04347200. [Av. at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04347200].2020."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD et al. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). The American Journal of Cardiology. 2018;122(10):1638\u201346. DOI: 10.1016\/j.amjcard.2018.07.041","DOI":"10.1016\/j.amjcard.2018.07.041"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Pollack CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA et al. Idarucizumab for Dabigatran Reversal \u2014 Full Cohort Analysis. New England Journal of Medicine. 2017;377(5):431\u201341. DOI: 10.1056\/NEJMoa1707278","DOI":"10.1056\/NEJMoa1707278"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2019;380(14):1326\u201335. DOI: 10.1056\/NEJMoa1814051","DOI":"10.1056\/NEJMoa1814051"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Halvorsen S, Storey RF, Rocca B, Sibbing D, ten Berg J, Grove EL et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal. 2016;38(19):1455\u201362. DOI: 10.1093\/eurheartj\/ehw454","DOI":"10.1093\/eurheartj\/ehw454"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267\u2013315. DOI: 10.1093\/eurheartj\/ehv320","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Jensen BES, Hansen JM, Larsen KS, Junker AB, Lassen JF, Jensen SE et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. European Journal of Gastroenterology & Hepatology. 2017;29(10):1118\u201325. DOI: 10.1097\/MEG.0000000000000934","DOI":"10.1097\/MEG.0000000000000934"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bouhoutsos J, Barabas AP, Martin P. Arteriosclerosis, amputation and peptic ulcer. Postgraduate Medical Journal. 1972;48(565):671\u20132. DOI: 10.1136\/pgmj.48.565.671","DOI":"10.1136\/pgmj.48.565.671"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Jolobe OMP. The Association of Peptic Ulcer Disease and Abdominal Aortic Aneurysm. The American Journal of Medicine. 2019;132(9):e724. DOI: 10.1016\/j.amjmed.2019.03.047","DOI":"10.1016\/j.amjmed.2019.03.047"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87\u2013165. DOI: 10.1093\/eurheartj\/ehy394","DOI":"10.1093\/eurheartj\/ehy394"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Lip GYH, Collet J-P, Haude M, Byrne R, Chung EH, Fauchier L et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). EP Europace. 2019;21(2):192\u2013 3. DOI: 10.1093\/europace\/euy174","DOI":"10.1093\/europace\/euy174"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Crowe SE. Helicobacter pylori Infection. New England Journal of Medicine. 2019;380(12):1158\u201365. DOI: 10.1056\/NEJMcp1710945","DOI":"10.1056\/NEJMcp1710945"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology. 2017;112(2):212\u201339. DOI: 10.1038\/ajg.2016.563","DOI":"10.1038\/ajg.2016.563"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Gisbert JP, Kuipers EJ, Axon AT et al. Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence Consensus Report. Gut. 2017;66(1):6\u201330. DOI: 10.1136\/gutjnl-2016-312288","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology. 2018;16(7):992-1002.e6. DOI: 10.1016\/j.cgh.2018.03.013","DOI":"10.1016\/j.cgh.2018.03.013"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Parker WAE, Storey RF. Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal. 2019;40(24):1971\u20134. DOI: 10.1093\/eurheartj\/ehz102","DOI":"10.1093\/eurheartj\/ehz102"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. European Journal of Internal Medicine. 2017;37:19\u201324. DOI: 10.1016\/j.ejim.2016.10.007","DOI":"10.1016\/j.ejim.2016.10.007"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic Advances in Drug Safety. 2019;10:204209861880992. DOI: 10.1177\/2042098618809927","DOI":"10.1177\/2042098618809927"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients with Coronary Artery Disease: A Meta-Analysis. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22(2):142\u201352. DOI: 10.1177\/1074248416663647","DOI":"10.1177\/1074248416663647"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FYB, El-Hayek G et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2(1):e000248. DOI: 10.1136\/openhrt-2015-000248","DOI":"10.1136\/openhrt-2015-000248"},{"key":"ref28","unstructured":"FDA. Postmarket Drug Safety Information for Patients and Providers. Information on Clopidogrel Bisulfate (marketed as Plavix). 2010. [Internet] 2010. Available at: http:\/\/wayback.archive-it.org\/7993\/20170111075953\/http:\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm190836.htm"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine. 2010;363(20):1909\u201317. DOI: 10.1056\/NEJMoa1007964","DOI":"10.1056\/NEJMoa1007964"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ. Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials. Journal of the American Heart Association. 2013;2(1):e004564. DOI: 10.1161\/JAHA.112.004564","DOI":"10.1161\/JAHA.112.004564"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017;377(14):1319\u201330. DOI: 10.1056\/NEJMoa1709118","DOI":"10.1056\/NEJMoa1709118"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and\/or Aspirin in a Randomized, DoubleBlind, Placebo-Controlled Trial. Gastroenterology. 2019;157(2):403- 412.e5. DOI: 10.1053\/j.gastro.2019.04.041","DOI":"10.1053\/j.gastro.2019.04.041"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, FunckBrentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407\u201377. DOI: 10.1093\/eurheartj\/ehz425","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2019;41(4):543\u2013603. DOI: 10.1093\/eurheartj\/ehz405","DOI":"10.1093\/eurheartj\/ehz405"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GYH. Anticoagulant-related gastrointestinal bleeding \u2013could this facilitate early detection of benign or malignant gastrointestinal lesions? Annals of Medicine. 2014;46(8):672\u20138. DOI: 10.3109\/07853890.2014.952327","DOI":"10.3109\/07853890.2014.952327"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG et al. M nd Treatment of Cardiovascular Risk Factors in Outpatients with Atherothrombosis. JAMA. 2006;295(2):180\u20139. DOI: 10.1001\/jama.295.2.180","DOI":"10.1001\/jama.295.2.180"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B et al. Association of Multiple Enrichment Criteria with Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. Journal of the American College of Cardiology. 2019;73(25):3281\u201391. DOI: 10.1016\/j.jacc.2019.04.046","DOI":"10.1016\/j.jacc.2019.04.046"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1159\/763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:17:40Z","timestamp":1793639860000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,6,19]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2020.7.n1159","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,19]]}}}